Introduction
============

Cancer ranks itself the leading causes of death around the world. In 2019, 1,762,450 new cancer cases and 606,880 cancer deaths are projected to occur in the United States. It has become a universal public health issue [@B1]. The most distinguished feature of cancer, un-controlled cell proliferation being one of them, is that it can assault the other vicinal parts of the body and diffuse to other organs. We refer this process to metastases, and this process could later evolve into a major cause of death from cancer. The exact etiology of carcinogenesis has not been fully verified [@B2]. More and more evidence point to genetic variation in contributing to the initiation and progression of cancer [@B3], [@B4]. However, due to cancer\'s complexity in nature, with heterogeneity being one of is feature, identification of this susceptibility is still a puzzle for us and most correlation has not been ascertained. On the other hand, during the decades, it has become universally agreed that single nucleotide polymorphisms (SNPs) are a common type of genetic variations that is the most frequently studied in connection with cancer susceptibility and that it consequently can act as the markers of many cancers [@B5].

Hypoxia possesses a vital role in the maintenance of tumor microenvironments. Hypoxic tumor microenvironment triggers extensive cellular responses, such as angiogenesis, proliferation and invasion [@B6]. By adjusting the oxygen pressure that results in gene alteration, hypoxia may control tumor cell phenotypes [@B6]. Hypoxia-inducible factor 1 (HIF-1) is a major transcriptional regulator implicated in homeostasis of oxygen. Koshiji et al. illustrated that HIF-1 leads to genetic instability by restraining the DNA mismatching repair system (MSH2 and MSH6) [@B7]. HIF-1 is a dimeric protein complex that possesses two components known as α and β subunits [@B8]. Studies have demonstrated that HIF-1*α* plays a vital role in activating various genes that is significantly involved with cell adhesion, erythropoiesis, angiogenesis and glucose transportation in the process of cancer development and progress [@B9].

Mounting evidence provided that featuring a high tumor grade, HIF-1α is over-stated in numbers of human cancers, indicating that HIF-1α functions as an independent element of cancer prognosis [@B10]. *HIF-1α* has been a research hot spot and numerous SNPs in *HIF-1α* were identified, whose polymorphism known as 1772 C\>T (rs11549465 C\>T, Pro582Ser), having been the most widely investigation polymorphism. rs11549465 C\>T is a nonsynonymous SNP. Compared to the wild type, this polymorphic variant can tremendously enhance transcriptional activity in both normoxic and hypoxic environment in *in-vitro* studies [@B11]. Moreover, *HIF-1α* rs11549465 C\>T is linked to increased tumor microvessel density which makes contribution to the cancer progression. *HIF-1α* rs11549465 C\>T polymorphism was previously investigated in various types of cancer. Nevertheless, the conclusions obtained from previous epidemiological studies are inconsistent and contradictory. Thus, the relationship between *HIF-1α* rs11549465 C\>T polymorphism and cancer risk requires further exploration. Herein, we performed this more comprehensive meta-analysis on selected case-control studies in the aim of giving a more thorough demonstration of the association of *HIF-1α* rs11549465 C\>T polymorphism with cancer risk.

Materials and Methods
=====================

Publication search
------------------

We systematically searched EMBASE, PubMed, PMC, Wanfang and CNKI to retrieve relatively pertinent publications based on case-control studies (update to March 18, 2019). No language restriction is made for this analysis. The search terminology involved were as listed: 1) *hypoxia-inducible factor-1* or*HIF-1α* or rs11549465 or 1772 C\>T; 2) SNPs or polymorphisms or polymorphism or variants; 3) cancer or carcinoma or neoplasm or tumor. To acquire all qualified publications, we also reviewed the references of the selected studies.

Eligibility criteria
--------------------

Impertinent and irrelevant studies were excluded on primary stage. Elimination criteria were: if 1) the study population was not mapped out; 2) it is not case-control study; 3) lack of information in allele frequency. Other than that, editorials, reviews and meta-analysis were ruled out. Only case-control studies with detailed number of different genotypes for estimating odds ratios (ORs) with 95% confidence intervals (CIs) were taken into the final analysis.

Data extraction
---------------

Two authors (Hu-Nian Li and Ting He) were arranged to extract information of all the articles respectively. Items listed below were extracted from every single study: 1) authors name; 2) publication year; 3) ethnicity of the study subject; 4) cancer type; 5) allelic frequency; 6) quality score. Studies with scores ≤9 were of low quality, whereas those with scores \>9 were of high quality [@B12], [@B13]. All the disputable parts were compromised by discussion before consensus was made finally.

Statistical methods
-------------------

We first performed Hardy-Weinberg equilibrium (HWE) for the controls utilizing the goodness-of-fit test. Homozygous model, heterozygous model, recessive model, dominant model, and allele model were employed to determine the relationship between *HIF-1α* rs11549465 C\>T polymorphism and cancer risk by calculating ORs with the corresponding 95% CIs. Moreover, we conducted the stratification analysis by ethnicity, cancer type, source of control, and HWE in controls. We also used Chi square-base *Q*-test to gauge the presence of heterogeneity. The fixed-effect model was used to compute the pooled OR, given the studies were confirmed to be homogeneous (*P*\>0.10 for the *Q* test). Or the random-effect model should be used instead. Sensitivity analysis was undertaken on the base of re-calculation of the ORs and 95% CIs by excluding each study individually. In order to detect the presence of publication bias, Begg\'s funnel plot and Egger\'s linear regression were adopted simultaneously. We also performed the trial sequential analysis (TSA) to avoid the random errors caused by repeated significance testing and dispersed data [@B13]. Version 11.0 STATA (Stata Corporation, College Station, TX) was selected to generate all statistical analysis. All the statistics were two-sided with *P* value \<0.05 as a baseline significant finding.

Results
=======

Study characteristics
---------------------

The study workflow was graphically displayed in **Figure [1](#F1){ref-type="fig"}**. We first collected 196 articles of the interest by a comprehensive search in the above-mentioned databases. After a basic check-up on articles relevance and abstracts conciseness, 156 articles were ruled out, which left us a total of 40 articles for full text assessment. To expand its sample size to ensure statistical representativeness, we identified another 6 articles from retrieve studies, quantity adding up to 46 articles in total [@B14]-[@B59]. Ultimately, 46 articles with 49 studies were contained in this analysis. A total of 12920 cases and 13363 controls was enrolled into this study for analyzing (**Table [1](#T1){ref-type="table"})**.

Quantitative analysis
---------------------

The quantitative results of the meta-analysis were displayed in **Table [2](#T2){ref-type="table"}** and **Figure [2](#F2){ref-type="fig"}**. The results concluded that the rs11549465 C\>T polymorphism was significantly related to the increased risk of overall cancer under homozygous model (TT vs. CC: OR=2.06, 95% CI=1.34-3.16), recessive model (TT vs. CC/CT: OR=2.42, 95% CI=1.60-3.65); dominant model (CT/TT vs. CC: OR=1.21, 95% CI=1.04-1.40), and allele model (T vs. C: OR=1.29,95% CI =1.12-1.48). We failed to detect any distinguished relationship between rs11549465 C\>T and renal cell carcinoma (RCC), endometrial cancer, colorectal cancer, lung cancer, breast cancer, hepatocellular cancer (HCC) under all the five genetic models. However, we observed that the rs11549465 C\>T polymorphism could confer to increased risk in subgroups of prostate cancer (CT vs. CC/CT: OR=1.51, 95% CI=1.01-2.26; CT/TT vs. CC: OR=1.56, 95% CI=1.04-2.34; T vs. C: OR=1.54, 95% CI =1.05-2.25), cervical cancer (TT vs. CC: OR=7.63, 95% CI=1.83-31.8; TT vs. CC/CT: OR=6.60, 95% CI=2.07-21.0), oral cancer (TT vs. CC: OR=2.61, 95% CI=1.19-5.72; TT vs. CC/CT: OR=13.2, 95% CI=1.08-162), pancreatic cancer (TT vs. CC: OR=3.39, 95% CI=1.28-8.97; TT vs. CC/CT: OR=2.42, 95% CI=1.60-3.65) and other cancers (TT vs. CC: OR=2.62, 95% CI=1.24-5.55; TT vs. CC/CT: OR=2.64, 95% CI=1.26-5.56; T vs. C: OR=1.28, 95% CI=1.00-1.62).

When it comes to the stratification analysis by the ethnicity, significant increased risk was detected in Asians, Caucasians and mixed population. In terms of source of controls, either population-based controls or hospital-based controls were associated with the increase risk of cancer. Further subgroup analysis by HWE in controls revealed that no significant correlation was observed in subgroup of HWE≤0.05. As regard to the quality of publications, significant increased risk was detected in high-quality and low-quality publications.

Heterogeneity and sensitivity analysis
--------------------------------------

The *Q* test (*P*\<0.001) implied an existence of heterogeneity under all the genetic models. Thus, we adopted a random-effect model to produce ORs and 95% CIs. In addition, the sequential sensitivity analysis was performed to give an evaluation of the impact of a sole study on the pooled estimation. Given the attempt of omitting in each study incurred no statistical fluctuation of the pooled ORs, we have reason to believe that the meta-analysis\'s data is of great reliability (**Figure [3](#F3){ref-type="fig"}**).

Publication bias
----------------

From the shape of the Begg\'s funnel plot shown in **Figure [4](#F4){ref-type="fig"}**, no evidence of asymmetry was found. Egger\'s test\'s statistics also gives no evidence of publication bias among the studies.

Trial sequential analysis (TSA)
-------------------------------

The TSA showed that the cumulative z-curve did not cross both the traditional threshold and the TSA threshold, yet the accumulated information was sufficient, indicating that no further evidence was needed to verify the conclusion (**Figure [5](#F5){ref-type="fig"}**).

Discussion
==========

In the current meta-analysis, we systematically evaluate the relationship between *HIF-1α* rs11549465 C\>T polymorphism and cancer risk by using 49 case-control studies. Our analysis showed that *HIF-1α* rs11549465 C\>T polymorphism could increase risk of overall cancer risk and specific cancer risk. Among all the epidemical studies on the rs11549465 C\>T polymorphism and cancer risk, this could be by now the most comprehensive one.

The *HIF-1α* gene is located at chromosome 14q21-24. *HIF-1α* regulates the expression of hundreds of genes which moderates the vital cellular functions like proliferation, apoptosis, angiogenesis, glucose metabolism, erythropoiesis, and iron metabolism [@B60]. Due to the complex functional mechanism and regulatory roles of *HIF-1a* in hypoxic stress, the possible role of *HIF-1a* gene SNPs in cancer susceptibility has evoked intensive investigation. The most broadly studied *HIF-1α* polymorphism rs11549465 C\>T (Pro582Ser) could induce proline-to-serine amino acid substitutions. However, the exact role of rs11549465 C\>T polymorphism in cancer risk obtained from different studies remain inconclusive.

In 2001, Clifford et al. [@B14] carried out a first case-control study investigating the relationship between *HIF-1α* rs11549465 C\>T and cancer risk. However, association analysis between rs11549465 C\>T and RCC risk in panels of 20 cases and 44 non-neoplastic controls did not reveal allelic frequency differences. An investigation conducted by Konac et al. [@B21] using endometrial, ovarian, and cervical cancers in the Turkish population revealed that the rs11549465 C\>T polymorphism of the *HIF-1α* may contribute to risk of endometrial and cervical cancers. In a meta-analysis performed by Zhao et al. [@B10] in 2009 using 5387 controls and 4131 cancer cases, the *HIF-1α* rs11549465 C\>T polymorphism was reported to be related to increased cancer risk. In 2015, Li et al. [@B61] conducted an updated meta-analysis by enrolling 7807 cases and 8633 controls. They obtained a similar result that the *HIF-1α* rs11549465 C\>T polymorphism predispose to higher overall cancer risk. To better illustrate the relationship of interest, we hereby conducted this updated meta-analysis by using all the qualified publications with a total of 12920 cases and 13363 controls. The results revealed that *HIF-1α* rs11549465 C\>T polymorphism contributes to increased overall cancer risk. In a sense, this meta-analysis has succeeded in giving a clearer clue of the relationship between *HIF-1α* rs11549465 C\>T polymorphism and cancer risk.

In the current meta-analysis, we undertaken many measurements to increase the credibility of our conclusion. First and foremost, we included as many as qualified studies to expand the analyzed sample size, by incorporating studies not only pressed in English but also in Chinese. Second, we adopted the sensitivity analysis and the publication bias. However, several limitations could not be settled down. First, between-study heterogeneity exists, which might weaken the persuasiveness of the conclusion. Second, the relationship strength was only assessed by use of unadjusted estimates. Lacking original data, such as environment factor, adjustment analysis was absent. Third, most of the included studies were conducted among Asians and Caucasians. The lack of other ethnicities, such as Africans, compromised the generalization of the conclusion.

In a word, our finding has come to a fruition that *HIF-1α* rs11549465 C\>T polymorphism was significantly related to an increase in cancer risk. Our work no doubt will encourage more dedication into further elucidation of the etiology of cancer predisposition. However, with limited sample size of subgroup analysis, we must admit that this analysis is imperfect and thus in the future more case-control studies should be conducted with a larger size of samples.
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###### 

Main characteristics of included studies in the meta-analysis

  Surname         Year   Cancer type               Country       Ethnicity   Control source   Genotype method   Case   Control   HWE   Score                                      
  --------------- ------ ------------------------- ------------- ----------- ---------------- ----------------- ------ --------- ----- ------- ------ ----- ---- ------ --------- ----
  Clifford        2001   RCC                       UK            Caucasian   PB               PCR               30     5         0     35      110    27    6    143    0.018     6
  Tanimoto        2003   HNSCC                     Japan         Asian       PB               PCR-Sequencing    45     10        0     55      98     12    0    110    0.545     5
  Ollerenshaw     2004   RCC                       UK            Caucasian   PB               PCR               16     54        90    160     1      90    71   162    \<0.001   6
  Kuwai           2004   Colorectal cancer         Japan         Asian       PB               PCR-Sequencing    100    0         0     100     89     11    0    100    0.561     7
  Chau            2005   Prostate cancer           USA           Mixed       PB               PCR               161    29        6     196     179    14    3    196    0.002     6
  Ling            2005   ESCC                      China         Asian       PB               PCR-RFLP          84     11        0     95      93     11    0    104    0.569     6
  Fransen         2006   Colorectal cancer         Sweden        Caucasian   PB               PCR-RFLP          167    28        3     198     213    43    2    258    0.916     8
  Konac           2007   Cervical cancer           Turkey        Caucasian   HB               PCR-RFLP          10     14        8     32      68     37    2    107    0.229     7
  Konac           2007   Ovarian cancer            Turkey        Caucasian   HB               PCR-RFLP          34     14        1     49      68     37    2    107    0.229     5
  Konac           2007   Endometrial cancer        Turkey        Caucasian   HB               PCR-RFLP          4      12        5     21      68     37    2    107    0.229     5
  Orr-Urtreger    2007   Prostate cancer           Israel        Caucasian   PB               PCR-RFLP          287    99        16    402     217    80    3    300    0.137     10
  Li              2007   Prostate cancer           USA           Mixed       PB               PCR-RFLP          818    209       14    1041    175    13    0    188    0.623     10
  Horre´e         2008   Endometrial cancer        Netherlands   Caucasian   PB               PCR               50     5         3     58      463    84    12   559    0.001     10
  Apaydin         2008   Breast cancer             Turkey        Caucasian   PB               PCR-RFLP          79     21        2     102     68     29    5    102    0.415     6
  Jacobs          2008   Prostate cancer           USA           Mixed       HB               MassARRAY         1156   252       12    1420    1138   284   28   1450   0.040     11
  Kim             2008   Breast cancer             Korea         Asian       HB               PCR-Sequencing    81     8         1     90      93     9     0    102    0.641     9
  Lee             2008   Breast cancer             Korea         Asian       PB               SNP-ITTM          1207   119       6     1332    1245   123   1    1369   0.250     11
  Nadaoka         2008   Bladder cancer            Japan         Asian       PB               PCR-RFLP          197    21        1     219     419    42    0    461    0.350     10
  Chen            2009   Oral cancer               China         Asian       PB               PCR-RFLP          163    10        1     174     334    13    0    347    0.722     9
  Li              2009   Gastric cancer            China         Asian       PB               PCR-LDR           83     4         0     87      93     13    0    106    0.501     6
  Naidu           2009   Breast cancer             Malaysia      Asian       PB               PCR-RFLP          294    100       16    410     222    50    3    275    0.922     10
  Foley           2009   Prostate cancer           Ireland       Caucasian   PB               PCR-Sequencing    65     30        0     95      175    13    0    188    0.623     9
  Muñoz-Guerra    2009   Oral cancer               Spain         Caucasian   PB               PCR               57     6         7     70      113    27    8    148    0.001     7
  Morris          2009   RCC                       UK            Caucasian   PB               Taqman            290    39        3     332     262    46    5    313    0.080     10
  Konac           2009   Lung cancer               Turkey        Caucasian   HB               PCR-RFLP          110    31        0     141     111    43    2    156    0.335     8
  Shieh           2010   OSCC                      China         Asian       HB               PCR-Sequencing    282    23        0     305     89     7     0    96     0.710     8
  Shieh           2010   Oral cancer               China         Asian       HB               PCR               187    12        0     199     89     7     0    96     0.710     8
  Chai            2010   Cervical cancer           China         Asian       HB               PCR               65     25        7     97      94     21    2    117    0.520     8
  Hsiao           2010   HCC                       China         Asian       HB               PCR-RFLP          94     8         0     102     334    13    0    347    0.722     9
  Kim             2011   Cervical cancer           Korea         Asian       HB               SNaPShot          177    22        0     199     187    27    0    214    0.325     9
  Putra           2011   Lung cancer               Japan         Asian       HB               PCR-Sequencing    74     9         0     83      98     12    0    110    0.545     9
  Wang            2011   Pancreatic cancer         China         Asian       HB               PCR-Sequencing    209    54        0     263     242    29    0    271    0.352     10
  Xu              2011   Glioma cancer             China         Asian       HB               PCR-RFLP          121    27        2     150     135    14    1    150    0.354     8
  Li              2012   Prostate cancer           China         Asian       HB               Taqman            612    48        2     662     659    57    0    716    0.267     10
  Ruiz-Tovar      2012   Pancreatic cancer         Spain         Caucasian   PB               PCR               47     1         11    59      116    28    8    152    0.0016    9
  Kuo             2012   Lung cancer               China         Asian       HB               PCR-RFLP          153    94        38    285     216    73    11   300    0.132     10
  Alves           2012   Oral cancer               Brazil        Mixed       PB               PCR               0      1         39    40      0      85    3    88     \<0.001   9
  Zagouri         2012   Breast cancer             Greece        Caucasian   HB               PCR-RFLP          98     15        0     113     107    17    0    124    0.413     5
  Qin             2012   RCC                       China         Asian       HB               Taqman            572    46        2     620     578    43    2    623    0.220     10
  Rebeiro         2013   Breast cancer             Portugal      Caucasian   PB               PCR-RFLP          74     21        1     96      61     7     4    72     0.001     8
  Mera-Menendez   2013   Glottic cancer            Spain         Caucasian   HB               PCR               85     18        15    118     114    27    8    149    0.001     10
  Fu              2014   Cervical cancer           China         Asian       HB               PCR               467    49        2     518     492    60    1    553    0.550     11
  Fraga           2014   Prostate cancer           Portugal      Caucasian   HB               Taqman            566    156       14    736     579    164   11   754    0.400     11
  Liu             2014   HCC                       China         Asian       HB               PCR-RFLP          152    4         1     157     162    11    0    173    0.6658    9
  Ni              2015   Digestive tract cancers   China         Asian       HB               PCR-RFLP          219    44        4     267     241    34    0    275    0.2745    10
  Meka            2015   Breast cancer             India         Asian       HB               PCR               245    94        9     348     229    89    2    320    0.0322    10
  Yamamoto        2016   Lung cancer               Japan         Asian       HB               TaqMan            405    55        2     462     341    37    1    379    0.9972    10
  Demirel         2017   Colorectal cancer         Turkey        Caucasian   HB               ARMS-PCR          62     27        3     92      81     16    4    101    0.0144    8
  Uslu            2018   Laryngeal Cancer          Turkey        Caucasian   HB               PCR               28     7         0     35      28     7     0    35     0.5109    5

HWE, Hardy-Weinberg equilibrium; PB, population based; HB, hospital based; RCC, renal cell carcinoma; HNSCC, head and neck squamous cell carcinoma; ESCC, esophageal squamous cell carcinoma; OSCC, oral squamous cell carcinoma; HCC, hepatocellular cancer; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.

###### 

Meta-analysis of *HIF-1α* rs11549465 C\>T polymorphism and cancer risk

  Variables           Homozygous                       Heterozygous                          Recessive      Dominant                         Allele                                                              
  ------------------- ---------------------- --------- -------------- ---------------------- ----------- -- ---------------------- --------- -------- ---------------------- --------- -- ---------------------- ---------
  All                 **2.06 (1.34-3.16)**   \<0.001                  1.14 (0.99-1.33)       \<0.001        **2.42 (1.60-3.65)**   \<0.001            **1.21 (1.04-1.40)**   \<0.001      **1.29 (1.12-1.48)**   \<0.001
  Cancer type                                                                                                                                                                                                    
  RCC                 0.37 (0.12-1.12)       0.282                    0.64 (0.32-1.29)       0.012          1.31 (0.77-2.24)       0.350              0.66 (0.35-1.23)       0.024        0.92 (0.70-1.19)       0.252
  Colorectal          1.30 (0.40-4.17)       0.579                    0.83 (0.24-2.83)       0.005          1.18 (0.37-3.78)       0.465              0.86 (0.29-2.60)       0.008        0.92 (0.37-2.26)       0.019
  Prostate            1.67 (0.66-4.19)       0.008                    **1.51 (1.01-2.26)**   \<0.001        1.62 (0.66-3.99)       0.011              **1.56 (1.04-2.34)**   \<0.001      **1.54 (1.05-2.25)**   \<0.001
  Cervical            **7.63 (1.83-31.8)**   0.170                    1.22 (0.76-1.96)       0.064          **6.60 (2.07-21.0)**   0.289              1.46 (0.78-2.72)       0.004        1.55 (0.80-3.02)       \<0.001
  Endometrial         9.06 (0.53-156.2)      0.014                    1.69 (0.18-16.2)       0.003          5.85 (0.93-36.9)       0.086              2.29 (0.25-21.1)       0.001        2.12 (0.46-9.78)       0.002
  Breast              1.38 (0.33-5.74)       0.045                    0.99 (0.80-1.23)       0.329          1.38 (0.33-5.75)       0.044              1.02 (0.85-1.22)       0.458        1.04 (0.88-1.23)       0.434
  Oral                **2.61 (1.19-5.72)**   0.514                    1.06 (0.61-1.85)       0.081          **13.2 (1.08-162)**    \<0.001            1.24 (0.79-1.93)       0.149        1.90 (0.88-4.07)       \<0.001
  Lung                1.92 (0.35-10.5)       0.103                    1.19 (0.78-1.82)       0.044          1.93 (0.43-8.66)       0.154              1.23 (0.71-2.13)       0.002        1.23 (0.69-2.20)       \<0.001
  HCC                 3.20 (0.13-79.1)       \-                       0.96 (0.17-5.29)       0.021          3.33 (0.14-82.2)       \-                 1.06 (0.24-4.68)       0.035        1.15 (0.33-4.06)       0.061
  Pancreatic          **3.39 (1.28-8.97)**   \-                       0.50 (0.02-14.0)       0.001          **2.42 (1.60-3.65)**   \-                 1.39 (0.54-3.56)       0.032        **1.75 (1.23-2.51)**   0.349
  Others              **2.62 (1.24-5.55**)   0.784                    1.13 (0.87-1.47)       0.275          **2.64 (1.26-5.56)**   0.810              1.22 (0.95-1.57)       0.274        **1.28 (1.00-1.62)**   0.239
  Ethnicity                                                                                                                                                                                                      
  Caucasian           1.54 (0.81-2.87)       \<0.001                  1.01 (0.75-1.35)       \<0.001        **1.82 (1.15-2.89)**   0.004              1.10 (0.84-1.44)       \<0.001      1.21 (0.97-1.51)       \<0.001
  Asian               **4.07 (2.61-6.34)**   0.995                    **1.19 (1.02-1.38)**   0.010          **3.67 (2.37-5.72)**   0.997              **1.25 (1.06-1.47**)   0.001        **1.28 (1.09-1.51)**   \<0.001
  Mixed               1.27 (0.26-6.15)       0.028                    1.85 (0.70-4.86)       \<0.001        7.57 (0.31-184)        \<0.001            1.86 (0.67-5.16)       \<0.001      **3.24 (1.02-10.3)**   \<0.001
  Source of control                                                                                                                                                                                              
  PB                  1.61 (0.90-2.89)       0.014                    1.03 (0.76-1.40)       \<0.001        **2.51 (1.33-4.74)**   \<0.001            1.12 (0.85-1.47)       \<0.001      1.27 (0.99-1.62)       \<0.001
  HB                  **2.61 (1.39-4.91)**   \<0.001                  **1.17 (1.00-1.36)**   0.001          **2.36 (1.33-4.18)**   \<0.001            **1.25 (1.05-1.48)**   \<0.001      **1.30 (1.09-1.55)**   \<0.001
  HWE                                                                                                                                                                                                            
  \>0.05              **2.92 (1.34-3.16)**   0.015                    **1.20 (1.02-1.41)**   \<0.001        **2.71 (1.76-4.16)**   0.111              **1.26 (1.06-1.50)**   \<0.001      **1.30 (1.10-1.54)**   \<0.001
  ≤0.05               1.18 (0.59-2.36)       \<0.001                  0.91 (0.62-1.33)       \<0.001        2.10 (0.99-4.44)       \<0.001            1.04 (0.78-1.38)       0.002        1.24 (0.95-1.63)       \<0.001
  Score                                                                                                                                                                                                          
  \>9                 **2.26 (1.32-3.85)**   0.001                    1.13 (0.97-1.32)       \<0.001        **2.19 (1.32-3.63)**   0.004              **1.21 (1.02-1.43)**   \<0.001      **1.25 (1.05-1.49)**   \<0.001
  ≤9                  1.76 (0.84-3.67)       \<0.001                  1.10 (0.83-1.47)       \<0.001        **2.59 (1.31-5.14)**   \<0.001            1.18 (0.90-1.54)       \<0.001      **1.31 (1.03-1.67)**   \<0.001

Het, heterogeneity; RCC, renal cell carcinoma; HB, hospital based; PB, population based.
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